Pharmacogenetics of proliferation signal inhibitors (mTOR inhibitors) in renal transplantation

被引：0
作者：
不详
机构：
来源：
PHARMACOGENOMICS | 2012年 / 13卷 / 15期
关键词：
SIROLIMUS; EFFICACY;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1680 / 1681
页数：2
相关论文
共 50 条
  • [31] The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
    Todeschini, Letizia
    Cristin, Luca
    Martinino, Alessandro
    Mattia, Amelia
    Agnes, Salvatore
    Giovinazzo, Francesco
    CURRENT ONCOLOGY, 2023, 30 (06) : 5574 - 5592
  • [32] Growing experience with mTOR inhibitors in pediatric solid organ transplantation
    Ganschow, R.
    Pape, L.
    Sturm, E.
    Bauer, J.
    Melter, M.
    Gerner, P.
    Hoecker, B.
    Ahlenstiel, T.
    Kemper, M.
    Brinkert, F.
    Sachse, M. M.
    Toenshoff, B.
    PEDIATRIC TRANSPLANTATION, 2013, 17 (07) : 694 - 706
  • [33] Replacing calcineurin inhibitors with mTOR inhibitors in children
    Sindhi, R
    Seward, J
    Mazariegos, G
    Soltys, K
    Seward, L
    Smith, A
    Kosmach, B
    Venkataramanan, R
    PEDIATRIC TRANSPLANTATION, 2005, 9 (03) : 391 - 397
  • [34] Conversion from calcineurin inhibitors to mTOR inhibitors
    Bodziak, Kenneth A.
    Hrick, Donald E.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (04) : 351 - 356
  • [35] mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
    Jefferies, Reece
    Puttagunta, Harish
    Krishnan, Anoushka
    Irish, Ashley
    Swaminathan, Ramyasuda
    Olynyk, John K.
    FRONTIERS IN MEDICINE, 2022, 9
  • [36] The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation
    Eisen, Howard
    Yang, Xiaolan
    TRANSPLANTATION, 2006, 82 (08) : S13 - S18
  • [37] Can the Risk of Skin Cancer After Transplantation Be Reduced by mTOR Inhibitors?
    Carroll, Robert P.
    Chapman, Jeremy R.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 61 (05) : 698 - 700
  • [38] The Return of the mTOR Inhibitors Getting it Right in Patients After Cardiac Transplantation
    Eisen, Howard J.
    Hasni, Farhan
    Wang, Denise
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (06) : 651 - 653
  • [39] Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?
    Gonzalez-Vilchez, F.
    Vazquez de Prada, J. A.
    Paniagua, M. J.
    Gomez-Bueno, M.
    Arizon, J. M.
    Almenar, L.
    Roig, E.
    Delgado, J.
    Lambert, L.
    Perez-Villa, F.
    Sanz-Julve, M. L.
    Crespo-Leiro, M.
    Segovia, J.
    Lopez-Granados, A.
    Martinez-Dolz, L.
    Mirabet, S.
    Escribano, P.
    Diaz-Molina, B.
    Farrero, M.
    Blasco, T.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (01) : 15 - 23
  • [40] Results of 4-Year Analysis of Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Patients: Single-Center Experience
    Sert, Mehmet
    Celik, Ali
    Kural, Kemal
    Ersan, Sibel
    Ataca, Pinar
    Atila, Koray
    Cavdar, Caner
    Sifil, Aykut
    Bora, Seymen
    Gulay, Huseyin
    Camsari, Taner
    RENAL FAILURE, 2011, 33 (08) : 789 - 794
12345